Carrie Cox, Executive Board Chair* Joseph Morrissey, Interim CEO* Juan Camilo Arjona Ferreira, M.D., Head of Research & Development and Chief Medical Officer* Aaron Falcione, Chief Human Resources Officer* Daniel Karp, Head of Corporate Development & Chief Strategy Officer* Tom Merriam, Chief of Staff Vittorio Nisita, Head of Enterprise Services & Solutions* Rachel Stahler, Chief Digital & Commercial […]
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced the appointment of Juan Camilo Arjona Ferreira, M.D., as Chief Medical Officer (CMO) and Charlotte Owens, M.D., as Head of Medical Affairs and Outcomes Research, strengthening the company’s global clinical and medical capabilities, advancing external relationships and fueling efforts to bring forward innovations to solve unmet health needs. Both positions report directly to Sandra Milligan, M.D., J.D., Head of Research and Development. Dr. Arjona Ferreira brings over two decades of clinical research and development experience and a strong background in women’s health. Most recently, he was CMO of Myovant Sciences Inc., and has previously held leadership roles in women’s health and other therapeutic areas at Shionogi and Merck, known as MSD outside of the United States and Canada. Earlier in his career, Dr. Arjona Ferreira practiced as an OB-GYN in university hospitals and private practice.
JERSEY CITY, N.J., DECEMBER 5, 2023 – Organon ( NYSE: OGN ) today announced that Dr. Sandra Milligan, global Head of Research and Development, will be leaving the company on January 5, 2024. Effective January 1, 2024, Dr. Juan Camilo Arjona Ferreira will assume the role of Head of Research and Development in addition to his current responsibilities as the company’s Chief Medical Officer. “I am grateful to Sandy for her contributions to the executive leadership team as we shaped Organon’s commitment to women’s health. She helped to establish this company, built a strong team and fostered a strong culture,” said Kevin Ali, Organon’s CEO. “Sandy has also been an incredible ambassador for Organon as we’ve established our reputation as a women’s health company.” Since 2021, Dr. Milligan has led Organon’s efforts to expand its women’s health focus from contraception and fertility to include products and research in areas such as post-partum hemorrhage, bacterial vaginosis, polycystic ovary
https://www.organon.com/news/organon-announces-new-head-of-research-and-development/
Weaver officially takes on role after becoming interim head of the Office of General Counsel and Corporate Secretary in July 2022 Organon (NYSE: OGN), a global women’s healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will continue as a member of Organon’s executive leadership team, effective January 1, 2023. Mr. Weaver was named as the interim head of the Office of General Counsel and Corporate Secretary in July 2022. Kirke Weaver (Photo: Business Wire) Mr. Weaver brings nearly 20 years of pharmaceutical industry experience to the role, successfully providing legal and business advice in the multi-faceted, changing healthcare environment. Prior to serving as interim General Counsel and Corporate Secretary, Mr. Weaver served as Senior Vice President, Commercial, Regulatory, Securities, Employment and Deputy Corporate Secretary at Organon. As a senior member of the legal leadership team, he was critical to launching
Only company of its size focused on women’s health Launching with a commitment to listen to women to understand her health needs and help identify solutions that are urgently needed Organon (NYSE: OGN), today celebrates its launch as a global women’s health company with employees and women from around the world, as the Organon executive leadership team rings the opening bell at the New York Stock Exchange (NYSE). Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602006054/en/ Organon is committed to women’s everyday health needs, with a focus on reproductive health, health issues that are unique to women, as well as conditions that disproportionately affect women. The “Wall of Voices” shares
https://www.organon.com/news/organon-launches-as-new-global-womens-health-company/
Jersey City, NJ, October 27, 2025 - Organon (NYSE: OGN) (“Organon” or “the company”) today announced that its Board of Directors has appointed the Company’s Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director. These appointments follow the resignation of Kevin Ali as Chief Executive Officer and member of the Board in connection with the Audit Committee investigation described below. Mr. Ali has agreed that he will not be entitled to severance or equity-related retirement benefits in connection with his resignation. After concerns regarding the Company’s wholesaler sales practices for its Nexplanon® product were brought to the Board’s attention, the Audit Committee of the Board oversaw an independent,
Kirke serves as the senior legal adviser and is responsible for Organon’s worldwide legal affairs, compliance and global ESG and corporate responsibility functions. He is focused on ensuring the company maintains the highest ethical standards and responsible business practices, which will help drive Organon to achieve its goal to be the leading women’s healthcare company. […]
https://www.organon.com/leadership/kirke-weaver-general-counsel-and-corporate-secretary/
Standalone company positioned to deliver low to mid-single digit revenue growth off 2021 base Future growth opportunities include Women’s Health and Biosimilars businesses; Established Brands portfolio expected to provide significant cash flow to invest in new opportunities, with modest future LOE risk after 2021 Organon will have a diverse product portfolio with no product representing more than 11% of total revenue, and an expansive global geographic footprint with nearly 80% of revenue generated outside the U.S. Experienced management team and majority-female Board of Directors focused on the vision to create a better and healthier every day for every woman around the globe Organon will begin regular way trading on the New York Stock Exchange under ticker symbol “OGN” on June 3 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will host Organon management at a meeting with the investment community. Management will detail plans for how Organon is expected
The heart of our company
https://www.organon.com/about-organon/mission-vision-and-values/inclusion-innovation-belonging/
We aim to deliver long-term value for women, employees and shareholders.
